{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:14:11Z","timestamp":1786976051577,"version":"build-2736575974"},"update-to":[{"DOI":"10.1002\/14651858.cd001415.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000}}],"reference-count":46,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd001415.pub4","type":"journal-article","created":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T04:27:11Z","timestamp":1610684831000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Gabapentin add-on treatment for drug-resistant focal epilepsy"],"prefix":"10.1002","volume":"2021","author":[{"given":"Mariangela","family":"Panebianco","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Pharmacology; Institute of Translational Medicine, University of Liverpool; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Al-Bachari","sequence":"additional","affiliation":[{"name":"Department of Neurology; Royal Preston Hospital; Preston UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane L","family":"Hutton","sequence":"additional","affiliation":[{"name":"Department of Statistics; University of Warwick; Coventry UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony G","family":"Marson","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Pharmacology; Institute of Translational Medicine, University of Liverpool; Liverpool UK"},{"name":"The Walton Centre NHS Foundation Trust; Liverpool UK"},{"name":"Liverpool Health Partners; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,1,12]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD001415.pub4-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/j.1528-1157.1994.tb02513.x","article-title":"Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study","volume":"35","author":"Anhut","year":"1994","journal-title":"Epilepsia"},{"issue":"8","key":"10.1002\/14651858.CD001415.pub4-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/j.1528-1157.1999.tb00833.x","article-title":"Gabapentin as add-on therapy in children with refractory partial seizures: a 12 week, multicentre, double blind placebo controlled study","volume":"40","author":"Appleton","year":"1999","journal-title":"Epilepsia"},{"issue":"6","key":"10.1002\/14651858.CD001415.pub4-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1212\/WNL.56.6.743","article-title":"Rapid Initiation of gabapentin: a randomised control trial","volume":"56","author":"Fisher","year":"2001","journal-title":"Neurology"},{"issue":"12","key":"10.1002\/14651858.CD001415.pub4-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1212\/WNL.0000000000003118","article-title":"Adjunctive pregabalin vs gabapentin for focal seizures: interpretation of comparative outcomes","volume":"87","author":"French","year":"2016","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD001415.pub4-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/jnnp.62.4.372","article-title":"Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy","volume":"62","author":"Leach","year":"1997","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"10","key":"10.1002\/14651858.CD001415.pub4-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/j.1528-1157.2000.tb04607.x","article-title":"Gabapentin versus vigabatrin as first add-on for patients with partial seizures that failed to respond to monotherapy: a randomised, double-blind, dose titration study","volume":"41","author":"Lindberger","year":"2000","journal-title":"Epilepsia"},{"issue":"3","key":"10.1002\/14651858.CD001415.pub4-BIB0007|cit7","first-page":"359","article-title":"Gabapentin and lamotrigine in Indian patients of partial epilepsy refractory to carbamazepine","volume":"50","author":"Sethi","year":"2002","journal-title":"Neurology India"},{"issue":"4","key":"10.1002\/14651858.CD001415.pub4-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1528-1157.1991.tb04689.x","article-title":"Double blind study of gabapentin in the treatment of partial seizures","volume":"32","author":"Sivenius","year":"1991","journal-title":"Epilepsia"},{"issue":"2","key":"10.1002\/14651858.CD001415.pub4-BIB0009|cit9","first-page":"151","article-title":"Gabapentin as adjuvant therapy in the treatment of refractory partial epilepsy","volume":"56","author":"Tomovic","year":"1999","journal-title":"Vojnosanitetski Pregled"},{"issue":"8698","key":"10.1002\/14651858.CD001415.pub4-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/0140-6736(90)91123-R","article-title":"Gabapentin in partial epilepsy","volume":"335","author":"UK Gabapentin Study Group","year":"1990","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD001415.pub4-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1212\/WNL.43.11.2292","article-title":"Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study","volume":"43","author":"US Gabapentin Study Group No 5","year":"1993","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD001415.pub4-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1440-1819.2006.01553.x","article-title":"Treatment of partial seizures with gabapentin: double-blind, placebo-controlled, parallel-group study","volume":"60","author":"Yamauchi","year":"2006","journal-title":"Psychiatry and Clinical Neurosciences"},{"issue":"4","key":"10.1002\/14651858.CD001415.pub4-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s40263-013-0048-z","article-title":"Pharmacotherapy of focal epilepsy in children: a systematic review of approved agents","volume":"27","author":"Arya","year":"2013","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1002\/14651858.CD001415.pub4-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/bcp.12083","article-title":"Comparative efficacy and tolerability of anti-epileptic drugs for refractory focal epilepsy: systematic review and network meta-analysis reveals the need for long term comparator trials","volume":"76","author":"Bodalia","year":"2013","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD001415.pub4-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/ajhp\/52.1.61","article-title":"Gabapentin and lamotrigine: novel antiepileptic drugs","volume":"52","author":"Btaiche","year":"1995","journal-title":"American Journal of Health-system Pharmacy"},{"issue":"6","key":"10.1002\/14651858.CD001415.pub4-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1136\/jnnp.50.6.682","article-title":"Gabapentin as an antiepileptic drug in man","volume":"50","author":"Crawford","year":"1987","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD001415.pub4-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/epi.12913","article-title":"Quality-of-life outcomes of initiating treatment with standard and newer antiepileptic drugs in adults with new-onset epilepsy: findings from the SANAD trial","volume":"56","author":"Jacoby","year":"2015","journal-title":"Epilepsia"},{"issue":"1","key":"10.1002\/14651858.CD001415.pub4-BIB0018|cit18","first-page":"19","article-title":"Comparative clinical trial of gabapentin and sodium valproate as add-on therapy in refractory partial epilepsies: open randomized multicenter trial","volume":"4","author":"Korean Gabapentin Study Group","year":"2000","journal-title":"Journal of Korean Epilepsy Society"},{"issue":"3","key":"10.1002\/14651858.CD001415.pub4-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.braindev.2013.04.006","article-title":"The efficacy of gabapentin in children of partial seizures and the blood levels","volume":"36","author":"Nonoda","year":"2014","journal-title":"Brain & Development"},{"issue":"5","key":"10.1002\/14651858.CD001415.pub4-BIB0020|cit20","first-page":"931","article-title":"New antiepileptic drugs: characteristics and clinical applications","volume":"72","author":"Ohtsuka","year":"2014","journal-title":"Japanese Journal of Clinical Medicine"},{"issue":"6 Suppl 5","key":"10.1002\/14651858.CD001415.pub4-BIB0021|cit21","first-page":"S23","article-title":"Clinical efficacy and safety of gabapentin","volume":"44","author":"Ramsay","year":"1994","journal-title":"Neurology"},{"issue":"10","key":"10.1002\/14651858.CD001415.pub4-BIB0022|cit22","first-page":"580","article-title":"Recommendations for the treatment of partial epilepsies with gabapentin A - a consensus","volume":"20","author":"Schmidt","year":"2001","journal-title":"Nervenheilkunde"},{"issue":"2","key":"10.1002\/14651858.CD001415.pub4-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1684\/epd.2014.0650","article-title":"Early add-on treatment vs alternative monotherapy in patients with partial epilepsy","volume":"16","author":"Semah","year":"2014","journal-title":"Epileptic Disorders"},{"issue":"Suppl Florence","key":"10.1002\/14651858.CD001415.pub4-BIB0024|cit24","first-page":"69","article-title":"A double blind study of gabapentin in partial seizures","volume":"41","author":"Kwan","year":"2000","journal-title":"Epilepsia"},{"issue":"Suppl 7","key":"10.1002\/14651858.CD001415.pub4-BIB0025|cit25","first-page":"106, Abstract n","article-title":"Gabapentin as add-on therapy for refractory partial seizures in children 1-36 months of age: a novel, short-term, placebo-controlled trial","volume":"41","author":"Shapiro","year":"2000","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001415.pub4-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/978-94-017-8914-1_24","article-title":"What are the arguments for and against rational therapy for epilepsy?","volume":"813","author":"Barker-Haliski","year":"2014","journal-title":"Advances in Experimental Medicine and Biology"},{"key":"10.1002\/14651858.CD001415.pub4-BIB0027|cit27","unstructured":"British National Formulary www.bnf.org\/"},{"issue":"8968","key":"10.1002\/14651858.CD001415.pub4-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0140-6736(95)91208-8","article-title":"Remission of epilepsy: results from the National General Practice Study of Epilepsy","volume":"346","author":"Cockerell","year":"1995","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD001415.pub4-BIB0029|cit29","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro GDT"},{"issue":"3","key":"10.1002\/14651858.CD001415.pub4-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1528-1157.1993.tb02586.x","article-title":"Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984","volume":"34","author":"Hauser","year":"1993","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001415.pub4-BIB0031|cit31","unstructured":"Higgins JP Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1"},{"key":"10.1002\/14651858.CD001415.pub4-BIB0032|cit32","doi-asserted-by":"crossref","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604"},{"key":"10.1002\/14651858.CD001415.pub4-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"c365","DOI":"10.1136\/bmj.c365","article-title":"The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews","volume":"340","author":"Kirkham","year":"2010","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD001415.pub4-BIB0034|cit34","unstructured":"Lefebvre C Glanville J Briscoe S Littlewood A Marshall C Technical Supplement to Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston MS, Li T, Page MJ, et al (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020 Available from www.training.cochrane.org\/handbook"},{"issue":"3","key":"10.1002\/14651858.CD001415.pub4-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0165-6147(00)01974-X","article-title":"Current status and future directions in the pharmacotherapy of epilepsy","volume":"23","author":"Loscher","year":"2002","journal-title":"Trends in Pharmacological Sciences"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD001415.pub4-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1111\/j.1528-1157.1995.tb06001.x","article-title":"Gabapentin","volume":"36","author":"McClean","year":"1995","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001415.pub4-BIB0037|cit37","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4899-3242-6","volume-title":"Generalized Linear Models","author":"McCullagh","year":"1989"},{"issue":"4","key":"10.1002\/14651858.CD001415.pub4-BIB0038|cit38","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002896.pub2","article-title":"Vagus nerve stimulation for partial seizures","author":"Panebianco","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD001415.pub4-BIB0039|cit39","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"issue":"4","key":"10.1002\/14651858.CD001415.pub4-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1528-1157.1981.tb06158.x","article-title":"Phenytoin monotherapy for epilepsy: a long term prospective study, assisted by serum level monitoring, in previously untreated patients","volume":"22","author":"Reynolds","year":"1981","journal-title":"Epilepsia"},{"issue":"4","key":"10.1002\/14651858.CD001415.pub4-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001415.pub4-BIB0042|cit42","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G Oxman A Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013 Available from gdt.guidelinedevelopment.org\/app\/handbook\/handbook.html"},{"issue":"6","key":"10.1002\/14651858.CD001415.pub4-BIB0043|cit43","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010541.pub3","article-title":"Surgery for epilepsy","author":"West","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD001415.pub4-BIB0044|cit44","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001415.pub2","article-title":"Gabapentin add-on for drug-resistant partial epilepsy","author":"Al-Bachari","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD001415.pub4-BIB0045|cit45","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001415","article-title":"Gabapentin add-on for drug-resistant partial epilepsy","author":"Marson","year":"1999","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD001415.pub4-BIB0046|cit46","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001415.pub3","article-title":"Gabapentin add-on treatment for drug-resistant focal epilepsy","author":"Panebianco","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T09:09:35Z","timestamp":1626167375000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD001415.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Epilepsy Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,1,12]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001415.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,12]]}}}